Navigation Links
Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
Date:11/2/2010

PALO ALTO, Calif., Nov. 2, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) a clinical stage drug development company focused on developing drugs to treat cancer, announced that it has been awarded grants totaling $1,222,396 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP).  The grants are intended to advance five of Telik's ongoing therapeutic drug development programs including the company's most advanced investigational drug candidate, TELINTRA®, for the treatment of myelodysplastic syndrome (MDS).

"We are pleased that all five of the grant applications submitted under this program were awarded the maximum allocation," said Dr. Michael Wick, Telik Chairman and Chief Executive Officer. "These funds will provide non-dilutive capital for advancing our clinical development programs in oncology, an area of unmet medical need."

A Qualifying Therapeutic Discovery Project is one designed to either treat or prevent diseases or conditions by conducting studies or carrying out research protocols for the purpose of securing approval from the Food and Drug Administration.  Qualifying companies must have 250 or fewer employees.  The award payments were authorized on October 29, 2010.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta®, a cancer activated prodrug.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
9. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
10. Telik Announces Third Quarter 2009 Financial Results
11. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... WHIPPANY, N.J. , July 11, 2017  Bayer has ... across eight countries as part of its prestigious Bayer Hemophilia ... Children,s Hospital of Philadelphia and Uniformed ... are among the winners. Grant recipients were announced ... Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
(Date:7/10/2017)... July 10, 2017  US medical equipment and supply ... according to Medical Equipment & Supplies: United ... Focus Reports. Continued increases in demand for medical services ... the population and supported by gains in disposable personal ... supplies. New product introductions will also drive sales as ...
(Date:7/6/2017)... ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, is ... nutrition support. To celebrate its anniversary, ThriveRx recently launched a ... new look with improved organization to create the best user experience for ... ... "We,ve made several great strides ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... management assistance and financial consultations to communities in the greater Denver region, is ... native recently diagnosed with a very rare kind of epilepsy. , Until a ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen Miller Agency, a ... in the greater Birmingham area, is joining the Chris Hammond Youth Foundation in ... the region. , The Chris Hammond Youth Foundation maintains athletic facilities in rural ...
(Date:7/21/2017)... PHILADELPHIA (PRWEB) , ... July 21, 2017 , ... ... ARTZ Philadelphia and Theater of Witness , was awarded a $300,000 ... growing humanities program which fosters empathy, comfort with ambiguity and the recognition of ...
(Date:7/21/2017)... ... ... Margarian Law Firm has filed a class action lawsuit against Dr. Pepper ... Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In Gegham Margaryan ... claims on its bottle that it is made from real ginger. , When consumers ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... improve their chances of acceptance to a residency in a United States hospital. ... degrees outside the U.S. , According to data released by the ECFMG®, every ...
Breaking Medicine News(10 mins):